Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Inclusion Criteria: * High grade glioma was diagnosed by post-operation pathological method, and shows a relapse. * Before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, PET or MRS results show positive features. * The age of patient should be between 18 years old and 70 years old. * The condition of the patient permits the treatment of ultra-low dose Bevacizumab plus Temozolomide. * The patient is informed consent,and willing to join in this research. Exclusion Criteria: * The diagnosis is not recurrent high-grade glioma. * The diagnosis of high-grade glioma was not established by pathological method. * The results of imageological examinations do not meet the standard of including. * The age of the patient does not meet the requirement of this research. * The condition of the patient does not permit the treatment of ultra-low dose Bevacizumab plus Temozolomide. * There are other conditions that the clinicians believe that the treatment of ultra-low dose Bevacizumab plus Temozolomide is not appropriate for the patient. * The patient is not willing to join in this research.